Literature DB >> 16451401

Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.

Chang-Ki Min1, Seok Lee, Yoo-Jin Kim, Ki-Seong Eom, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim, Chul-Soo Cho, Gyeongsin Park.   

Abstract

The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-kappaB (NFkappaB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-alpha, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16451401     DOI： 10.1111/j.0902-4441.2005.t01-1-EJH2437.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  9 in total

1.  Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases.

Authors:  Peter Arne Gerber; Edwin Bölke; Bettina Alexandra Buhren; Daniela Bruch-Gerharz; Roland Fenk; Julia Reifenberger; Wilfried Budach; Rainer Haas; Bernhard Homey
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis.

Authors:  Anoop D Shah; Andrew J B Watts; Atul B Mehta; Ashutosh D Wechalekar
Journal:  Int J Hematol       Date:  2009-12-18       Impact factor: 2.490

3.  T-cell pseudolymphoma secondary to ixazomib for multiple myeloma.

Authors:  M Haq; Y Reyal; N Tiffin; S Szakacs; L Ferguson
Journal:  Skin Health Dis       Date:  2021-06-30

4.  Ixazomib-induced cutaneous necrotizing vasculitis.

Authors:  A Alloo; H Khosravi; S R Granter; S M Jadeja; P G Richardson; J J Castillo; N R LeBoeuf
Journal:  Support Care Cancer       Date:  2018-02-01       Impact factor: 3.603

5.  Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

Authors:  Dai Maruyama; Takashi Watanabe; Yuji Heike; Kumiko Nagase; Noriko Takahashi; Satoshi Yamasaki; Fusako Waki; Hiroki Yokoyama; Sung-Won Kim; Yukio Kobayashi; Shin Aizawa; Kensei Tobinai
Journal:  Int J Hematol       Date:  2008-11-07       Impact factor: 2.490

6.  Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation.

Authors:  Sarah J Cullen; Subramaniam Ponnappan; Usha Ponnappan
Journal:  Biochem Pharmacol       Date:  2009-10-14       Impact factor: 5.858

7.  Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.

Authors:  Tomoko Ikeda; Hiroshi Fujii; Masato Nose; Yukiko Kamogawa; Tsuyoshi Shirai; Yuko Shirota; Tomonori Ishii; Hideo Harigae
Journal:  Arthritis Res Ther       Date:  2017-08-11       Impact factor: 5.156

8.  Molecular Insight Into the IRE1α-Mediated Type I Interferon Response Induced by Proteasome Impairment in Myeloid Cells of the Brain.

Authors:  Maja Studencka-Turski; Gonca Çetin; Heike Junker; Frédéric Ebstein; Elke Krüger
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

9.  Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.

Authors:  Kazutake Yoshizawa; Harumi Y Mukai; Michiko Miyazawa; Makiko Miyao; Yoshimasa Ogawa; Kazuma Ohyashiki; Takao Katoh; Masahiko Kusumoto; Akihiko Gemma; Fumikazu Sakai; Yukihiko Sugiyama; Kiyohiko Hatake; Yuh Fukuda; Shoji Kudoh
Journal:  Cancer Sci       Date:  2014-01-21       Impact factor: 6.716
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.